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Abstract 
 
The pharmacological targeting of cholesterol levels continues to draw interest due to 
the vast success of therapeutics such as statins in extending life expectancy by 
modifying the prognosis of diseases associated with the impairment of the lipid 
metabolism. Advances in our understanding of mitochondrial dysfunction in chronic 
age-related diseases of the brain have unveiled an emerging role for mitochondrial 
cholesterol (mChol) in their pathophysiology, thus delineating an opportunity to provide 
mechanistic insights and explore strategies of intervention. This review draws attention 
to novel signalling mechanisms in conditions linked with impaired metabolism 
associated with impaired handling of cholesterol and its oxided forms (oxysterols) by 
mitochondria. By emphasising the role of mChol in neurological diseases we here call 
for novel approaches as well as new means of assessment. 
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Abbreviations 
 
mChol Mitochondrial cholesterol 
ER-MAM endoplasmic reticulum-mitochondria associated membrane 
ER endoplasmic reticulum 
mtDNA mitochondrial DNA 
AD Alzheimers disease 
ROS reactive oxygen species 
7β-OHC 7β-hydroxycholesterol 
7-KC 7-ketocholesterol 
CNS central nervous system 
IMM Inner mitochondrial membrane 
ATAD3 ATPase family AAA domain-containing protein 3 
APOE4 apolipoprotein isoform 4 
LDLr low density lipoprotein receptor 
AßPP amyloid ß precursor protein 
Aß amyloid ß peptide 
StAR steroidogenic acute regulatory protein 
VDAC1 voltage-dependent anion selective channel 1 
ACBD1/3 Acyl-coenzyme A binding domain containing 3 
TSPO translocator protein 
OMM Outer Mitochondrial Membrane 
ANT adenine nucleotide transporter 
CYP11A1 Cytochrome P450 Family 11 Subfamily A Member 1 
PD Parkinson’s Disease 
MPTP 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine 
MPP+ 1-methyl-4-phenylpyridinium 
HD Huntington’s Disease 
HTT huntingtin protein 
ALS amyotrophic lateral sclerosis 
24-OHC 24-hydroxycholesterol 
27-OHC 27-hydroxycholesterol 
4α-OHC 4α-hydroxycholesterol 
4β-OHC 4β-hydroxycholesterol 
α-epoxy C α-epoxy cholesterol 
β-epoxy C β-epoxy cholesterol 
25-OHC 25-hydroxycholesterol 
7α-OHC 7α-hydroxycholesterol 
SOD1 superoxide dismutase 1 
LXR liver-X receptor 
MitoQ 
10-(4,5-dimethoxy-2-methyl-3,6-dioxo-1,4-cyclohexadien-1-yl)decyl 
triphenylphosphonium methane sulfonate 
CoQ10 Coenzyme Q10 
SkQ1 10-(6'-plastoquinonyl) decyltriphenylphosphonium 
 
Introduction 
 
 
Cholesterol has emerged as a keystone lipid in mammalian cellular physiology and 
pathology since it was identified as bile solid in gallstones in 1769 by François 
Poulletier de la Salle. Cholesterol promotes an increase in lipid conformational order 
thus providing protection to animal cells (Simons & Ikonen, 1997) besides being a 
precursor for steroid hormones, bile acids and vitamin D. The insertion of cholesterol 
into various organellar membranes lends rigidity to these and offers protein-tethering 
platforms such as in the case of synaptic lipid rafts or ER-MAM (Endoplasmic 
Reticulum-mitochondria associated membrane) structures (Fujimoto, Hayashi & Su, 
2012; Lajoie, Goetz, Dennis & Nabi, 2009). 
 
Cholesterol is loaded differently among organelles and intracellular compartments. For 
instance, the plasma membrane contains cholesterol 40-fold higher than the ER and 
mitochondria (Horvath & Daum, 2013). In the mitochondria cholesterol is a: (i) 
structural component of the inner and outer mitochondrial membranes; (ii) precursor 
of steroidogenesis (of which the first steps are conducted in the mitochondrial lumen); 
(iii) core to a platform of interaction with ER, lysosomes and other compartments; as 
well as (iv) a tethering element for mitochondrial DNA (mtDNA). As a consequence, 
alterations in mChol occur in several diseases amongst which Alzheimer’s disease 
(AD) and neurodegenerations (Desai et al., 2017; Elustondo, Martin & Karten, 2017). 
The juxtaposition of mChol with the respiratory chain complex where reactive oxygen 
species (ROS) are produced, creates ideal conditions for the production of auto- 
oxidative products of cholesterols: the oxysterols (Zerbinati & Iuliano, 2017) which are 
implicated in brain diseases too. Some oxysterols are intermediates of cholesterol 
metabolism, enzymatically transformed into bile acids, steroid hormones and vitamin 
D. Auto-oxidation of cholesterol by ROS also results in the formation of oxysterols 
implying a pro-pathological positive feedback which amplifies mitochondrial 
dysfunction and hence severity of the condition. 
7-hydroxycholesterol (7β-OHC), 7-ketocholesterol (7-KC) and 5,6-epoxides as well 
as the secosterols are all produced under oxidative stress. In keeping with this, the 
levels of several species of oxysterols reflect the degree of pathology in chronic 
Central Nervous System (CNS) conditions (Zerbinati & Iuliano, 2017). It remains 
unclear though, how these processes can be pharmacologically modulated to inform 
therapeutic protocols or re-purposing existing cholesterol targeting chemicals. Here 
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we overview our current knowledge of mChol homeostasis and its link to 
neurodegeneration to stem interest and encourage further exploitation of this lipid in 
mitochondrial physiopathology. 
 
 
 
Role of cholesterol in Mitochondrial DNA maintenance 
 
 
mtDNA is associated with nucleic acid binding proteins forming complexes known as 
nucleoids (Spelbrink, 2010). Mutations in mtDNA as well as in nuclear-encoded 
mitochondrial genes cause primary mitochondrial diseases (Gorman et al., 2016). 
Cholesterol rich patches in the mitochondrial inner membrane tether the mtDNA to the 
inner mitochondrial membrane (IMM) via nucleoprotein complexes called nucleoids. 
These patches and their components enable mtDNA processing, protein synthesis 
and replication (Gerhold et al., 2015; He et al., 2007). While the lipid composition of 
mitochondria has been described (Fleischer, Rouser, Fleischer, Casu & Kritchevsky, 
1967), dynamics of distribution and regulation remain fairly unexplored. Mitochondria 
are ‘cholesterol-poor’ organelles with a cholesterol to phospholipid ratio as low as 0.1 
(van Meer, Voelker & Feigenson, 2008). This low level of cholesterol is unlikely to form 
classical lipid rafts with close association with sphingolipids (Zheng, Berg & Foster, 
2009). However, from what is known about the behaviour of bilayer membranes and 
lipid movement, it can be inferred that cholesterol is restricted to nanodomains in the 
strict curvatures of the IMM (Rukmini, Rawat, Biswas & Chattopadhyay, 2001). This 
implies that rather than cholesterol-poor mitochondria they are cholesterol-vital 
organelles. The majority of primary mitochondrial diseases caused by mutations in the 
mtDNA associates with neurological deficits, ranging from mild ataxia to severe early 
onset of neurodegeneration (Carelli & La Morgia, 2018). Explorations into the mChol 
modulating proteins suggest that they directly impact mtDNA and hence associated 
mutations cause severe primary mitochondrial disorders. 
One of the components of nucleoprotein complex associated with mtDNA is the AAA+ 
ATPase protein ATPase family AAA domain-containing protein 3 (ATAD3), which has 
mtDNA binding properties (He et al., 2012; He et al., 2007). ATAD3 was found to affect 
the rate of steroidogenesis by facilitating cholesterol transport from ER to mitochondria 
(He et al., 2012; He et al., 2007; Issop et al., 2015). Mutations in the ATAD3 family of 
proteins which alter cholesterol metabolism, cause severe neurodegeneration, 
mitochondrial cristae defects and impaired mtDNA segregation (Desai et al., 2017; 
 
Peralta et al., 2018). Pharmacologically interfering with cholesterol shuttling in ATAD3 
deficient human fibroblasts via U18666A or by altering cholesterol biosynthesis via 
statins (e.g. pravastatin), results in exacerbated mtDNA de-segregation. Aggregation 
and disorganization imbalance are also observed in the Niemann-Pick type C disorder, 
further supporting the critical role of cholesterol inserts in mitochondria by controlling 
the tuned segregation of the organelle DNA (Desai et al., 2017). 
More recently, it has been also shown that deficiency in ATAD3 affects the formation 
of mitochondrial cristae (Peralta et al., 2018) suggesting that the optimum level of 
cholesterol inserts into the IMM is equally crucial in maintaining membrane structure 
as well as mtDNA integrity. Dysregulation of mChol may therefore result in primary 
mitochondrial dysfunction perturbing mtDNA homeostasis leading to deficits in the 
energy balance (Figure 1). 
 
 
 
 
Mitochondrial cholesterol and oxysterols in neurodegeneration 
 
 
Several studies have reported dysregulated cholesterol metabolism in AD and the E4 
variant of cholesterol gene apolipoprotein E(APOE) is a common risk factor for familiar 
AD  [as  comprehensively  reviewed  in  (Arenas,  Garcia-Ruiz  &  Fernandez-Checa, 
2017)]. However, less is understood about mChol in the disease. In a model of 
hypercholesterolemia, where low density lipoprotein receptor (LDLr-/-) mice are fed a 
high cholesterol diet, the mice develop cholesterol loading in the mitochondria and 
subsequent cognitive deficiencies and AD mimicking neurodegeneration. The cerebral 
cortex of LDLr-/- mice fed with cholesterol-enriched diet showed a (i) decrease in the 
activities of mitochondrial complexes I and II (ii), glutathione levels (iii), imbalance 
between the peroxide-removing-related enzymes (glutathione peroxidase and 
glutathione reductase) (de Oliveira et al., 2011). 
Del Prete et al studied a mutant form of Amyloid- precursor protein (A-PP) and found 
that there was an increased incidence of ER-MAM structures, which in turn captured 
more of the secretase-processed metabolites of the mutant A-PP in this micro-region 
thus interfering with MAM functions (Del Prete et al., 2017). 
This adds to the growing evidence that ER-MAM interactions are key platforms of AD 
aetiology (Area-Gomez et al., 2018). The AD peptide Amyloid-ß (Aß), when targeted 
to mitochondria, is thought to be crucially involved in associated toxicity. Aß induces 
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ER stress leading to the increased synthesis of cholesterol and loading into the 
mitochondria via ER-MAM structures. Additionally, enrichment of cholesterol in 
mitochondrial membranes is reported in AD pathology. 
Mitochondria from a mouse model of cholesterol overload exhibit-increased 
susceptibility to Aß-induced oxidative stress and consequent cytochrome c release 
(Fernandez, Llacuna, Fernandez-Checa & Colell, 2009). Coupled with this 
observation, loading of mitochondrial cholesterol is increased in AD mouse model 
(Fernandez, Llacuna, Fernandez-Checa & Colell, 2009), accompanied by an 
overexpression of the Steroidogenic Acute Regulatory (StAR) protein (Barbero- 
Camps, Fernandez, Baulies, Martinez, Fernandez-Checa & Colell, 2014; Hashimoto 
et al., 2018). StAR is a lipo-protein that transports cholesterol from the ER to 
mitochondria regulating the intra-organelle distribution of the lipid. 
Components of the “transduceome” are known to affect cholesterol processing in the 
mitochondria and steroidogenesis -including neurosteroidogenesis- making them an 
attractive target for pharmacological regulation of these important biological processes 
(Rone, Fan & Papadopoulos, 2009; Rone et al., 2012; Strobbe & Campanella, 2018). 
The transduceome, which has been studied more extensively in non-neuronal cells, is 
a complex of cholesterol binding proteins that orchestrate movement of cholesterol 
into the mitochondria. It comprises, the Voltage Dependent Anion Channel 1 (VDAC1) 
along with interacting partners, ACBD1/3, and, under steroidogenic conditions, 
Translocator Protein (TSPO) and StAR on the outer mitochondrial membrane (OMM). 
They connect with ATAD3 on the IMM via adenine nucleotide translocase (ANT) to 
deliver cholesterol to the processing enzyme Cytochrome P450 Family 11 Subfamily 
A Member 1 (CYP11A1) to generate pregnenolone - the first step of steroidogenesis 
(Rone, Fan & Papadopoulos, 2009; Rone et al., 2012). Under conditions of stress, 
such as neuroinflammation and neurodegeneration, the 18kDa TSPO is over- 
expressed to fuel the cholesterol processing machinery (Figure 1). Although the 
precise function of TSPO remains unresolved and likely boarder (Gatliff et al., 2014), 
the protein presents two validated cholesterol binding sites (Fantini, Di Scala, Evans, 
Williamson & Barrantes, 2016; Jaipuria et al., 2017; Jaremko, Jaremko, Giller, Becker 
& Zweckstetter, 2014). When bound to cholesterol TSPO changes confirmation 
(Jaipuria et al., 2017) implying that it has a key function in regulating intra-organellar 
distribution of cholesterol. As a result of a druggable structure (Jaremko, Jaremko, 
 
Giller, Becker & Zweckstetter, 2014) and temporally regulated expression, (Gavish & 
Veenman, 2018) TSPO has been a target of several generations of chemical PET 
tracers (positron emission tomography) and pharmaceutical ligands (Veenman, 
Vainshtein, Yasin, Azrad & Gavish, 2016) (see Table 1). 
In our opinion this represents an opportunity for exploration of potential protective 
effects by disrupting the transduceome with TSPO regulators (Gatliff & Campanella, 
2016). A better understanding of TSPO function, and its role of the steroidogenic 
transduceome in neuronal dysfunction is therefore necessary to lay a foundation for 
foreseeable therapeutic interventions. While cholesterol synthesis inhibitors such as 
the “blockbuster” statins (Cholesterol Treatment Trialists et al., 2015) occupy an elite 
place in cholesterol modulation, it is perhaps time to look beyond this strategy and turn 
to more subtle and selective mechanisms of cholesterol shuttling. The TSPO ligands 
are indeed exploited for anti-inflammatory and neuroprotective effects (Qiu et al., 
2016; Scholz et al., 2015). 
 
In a rat model of hypercholesterolaemia, ischemia-reperfusion injury results in 
mitochondrial sterol (both cholesterol and oxysterol) accumulation in mitochondria 
(Paradis, Leoni, Caccia, Berdeaux & Morin, 2013), which can be ablated by TSPO 
ligands SSR180575 (benzodiazepine), 4′-chlorodiazepam or TRO40303. This 
methodology may prove useful in diseases of the CNS where mitochondrial sterol 
levels are altered and the range of TSPO ligands (annotated in Table 1) can be a 
useful toolkit to explore this. 
Within the context of mitochondrial dysfunction, classically, the research on 
Parkinson’s disease (PD) has focussed on the deficiencies in quality control regulation 
of mitochondria by autophagy (Larsen, Hanss & Kruger, 2018). However, studies have 
shown that disrupted cholesterol dynamics associate with established molecular 
features of PD [reviewed in (Arenas, Garcia-Ruiz & Fernandez-Checa, 2017)]. One of 
the earliest evidence was in PD patients derived human fibroblasts which showed 50% 
reduction in cholesterol biosynthesis (Musanti, Parati, Lamperti & Ghiselli, 1993). 
Lim et al found that a cholesterol precursor lanosterol was 50% lower in a neurotoxin- 
induced mouse model (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)) of PD. 
This evidence was recapitulated in vitro where it was observed a redistribution of 
lanosterol synthase from the ER to mitochondria in dopaminergic neurons exposed to 
1-methyl-4-phenylpyridinium (MPP+) thus implying a survival effect via mitochondria 
 
(Lim et al., 2012). Similarly, in neuroblastoma cells treated with MPP+ there was 
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marked accumulation of cholesterol in lysosomes (Eriksson, Nath, Bornefall, Giraldo 
 
& Ollinger, 2017). When this effect was mimicked by cholesterol blocking agent 
U18666A, cell death was reduced, hinting that lysosomal cholesterol accumulation 
may be an adaptive stress response. Furthermore, cholesterol synthesis inhibitor 
lovastatin reduced MPP+- induced cell death by lowering ROS production without 
preventing the accumulation of cholesterol into lysosomes (Eriksson, Nath, Bornefall, 
Giraldo & Ollinger, 2017). This argues for further functions for mtChol: alike the ER- 
MAM communication also the lysosome-mitochondria communication is cholesterol 
dependent and the delicate balance of membrane lipid composition critical for healthy 
CNS. 
A recent publication by Lin et al (Lin et al., 2018), has shone light on the transcriptomic 
changes accompanying the isoform change of Apolipoprotein (APOE3  APOE4) 
which has for long been the largest genetic risk factor acknowledged for late onset 
sporadic AD. The authors dissected the transcriptomic changes in different types of 
derived CNS cells discovering that astrocytes, neurones, and microglia regulate 
different pathways to compensate for the loss of APOE4. Most notably, APOE4 
astrocytes have altered cholesterol metabolism, this is of particular interest because 
astrocytes are known to supply cholesterol to neurons. The gene-edited CNS cells 
exhibit other features of AD such as compromised A- clearance, altered synaptic 
formation, immune activation, increased A- production and hyperphosphorylated tau. 
Lin et al present in dish modelling of AD and a scientific validation for exploring 
cholesterol shuttling as a target for therapy. Perhaps, this balance of cholesterol at 
interorganellar interactions is key to mitochondrial network dynamics that ultimately 
define cellular health, especially in neurones, which are highly dependent on oxidative 
phosphorylation. In the case of familiar PD, in which deficiency impacts mitochondrial 
quality control by autophagy to the extent of dysfunction and ultimately death of the 
dopaminergic neurones, the ability to modulate mitophagy can prove critical. 
Mitochondrial cholesterol protein TSPO has an anti-mitophagy effect when 
overexpressed (Gatliff & Campanella, 2015; Gatliff et al., 2014). 
By disrupting the activity of TSPO via its ligands or changing its residence time on the 
mitochondria, efficient mitophagy could be restored and so cellular health. Intriguingly, 
modulation of mChol may allow the same beneficial outcome. This is supported by 
observations in pre-clinical as well as clinical studies, in which TSPO expression 
 
correlates with longitudinal progression of neurological conditions (Cumming & 
Borghammer, 2012; Maia et al., 2012). 
Unlike AD, other neurodegenerative diseases do not have such straightforward 
evidence of mChol involvement in their pathophysiology. We nonetheless know that 
Huntington’s disease (HD), the HTT (huntingtin protein)-induced mitochondrial fluidity 
can be rescued by olesoxime, a cholesterol-like product (Eckmann et al., 2014) which 
bears also neuroprotective effects in amyotrophic lateral sclerosis (ALS) (Martin, 
2010). 
 
 
 
 
 
Oxysterols – Schrodinger’s cat of mitochondrial cholesterol related dysfunction 
 
 
 
Cholesterol is present at the site of mitochondrial ROS production and susceptible to 
auto-oxidation into oxysterols making of these a metaphorical Schrodinger’s cat of 
neurodegeneration. Heightened oxysterol levels are being used as biomarkers for 
neurodegenerative diseases and lysosomal storage disorder progression (Griffiths et 
al., 2017; Testa et al., 2016). Cholesterol can be enzymatically broken down into  24- 
hydroxycholesterol (24-OHC) and  27-hydroxycholesterol (27-OHC), or auto-oxidised 
by ROS to products like 7-KC, 4α-hydroxycholesterol (4α-OHC), 4β- 
hydroxycholesterol (4β-OHC),  7β -OHC, α-epoxy cholesterol (α-epoxy C) and β-
epoxy cholesterol    (β-epoxy    C),    while     25-hydroxycholesterol    (25-OHC)    
and     7α- hydroxycholesterol (7α-OHC) can occur in both ways. When tested in AD 
(Alzheimer’s disease) patients, all of the above tested oxysterols are found elevated 
in late stage of  the condition  except  for  the enzymatic 24-OHC,  which  reduces  
with  disease progression (Testa et al., 2016). 
ALS is a primary target of exploited oxysterol signalling. Since the discovery that 
mutation in the mitochondrial anti-oxidant enzyme superoxide dismutase 1 (SOD1) 
can cause ALS (Ince, Shaw, Slade, Jones & Hudgson, 1996), mitochondrial oxidative 
stress in motor neurones has become a key research interest in the field. Recent 
studies have revealed that liver x receptors  and  (LXR and LXR-) are key 
players in ALS aetiology. LXRs are nuclear receptors of oxysterols, which regulate 
cholesterol synthesis amongst other cellular processes (dependent on the cellular 
type). A recent study  identified  two  single  nucleotide  polymorphisms  of  LXRα,  
rs2279238  and 
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rs7120118 associated with delayed age of ALS onset amongst a cohort of 330 ALS 
patients (Mouzat, Raoul, Polge, Kantar, Camu & Lumbroso, 2016). Moreover, male 
LXR-–/– mice develop severe motor impairment closely resembling ALS at 7 months 
which later progresses to hind-limb paralysis (Andersson, Gustafsson, Warner & 
Gustafsson, 2005). 
If autoxidative forms of oxysterols produced in the mitochondria are acknowledged 
contributing factors in ALS, beneficial are the antioxidant protocols adopted to 
ameliorate the condition. Miquel et al assessed the therapeutic benefit of a 
mitochondrially targeted anti-oxidant MitoQ (10-(4,5-dimethoxy-2-methyl-3,6-dioxo- 
1,4-cyclohexadien-1-yl) decyl triphenylphosphonium methane sulfonate) in a mouse 
model of familial ALS  in which decline of mitochondrial function was slowed down, in 
both the spinal cord and the quadriceps muscle (Miquel et al., 2014). 
While the preclinical data are substantive, no anti-oxidant therapy has, hitherto, proved 
to modify ALS or any other neurodegenerative condition. Intriguingly though, there are 
some reports of long term statins usage causing ALS, which is attributed to the parallel 
reduction of mitochondrial antioxidant Coenzyme Q10 (CoQ10) by the inhibition of 
HMG-CoA reductase enzyme (Edwards, Star & Kiuru, 2007). 
Testing other anti-oxidants such as 10-(6'-plastoquinonyl) decyltriphenylphosphonium 
(SkQ1), MitoQuercetin, Mitocurcumin, Mitoresveratrol, MitoHonokiol, Mitoapocynin, 
AntiOxCIN4, AntiOxBEN2, could anyway prove beneficial in ALS, more importantly in 
the models where the anti-oxidant system is disrupted (Teixeira, Deus, Borges & 
Oliveira, 2018). 
After almost 2 decades since the approval of Riluzole for ALS, only recently Edaravone 
was approved by the FDA (May 2017), showing benefit in a randomized double-blind 
clinical trial (Rothstein, 2017; Writing & Edaravone, 2017). While Edaravone has other 
effects, such as reducing inflammation, its main activity is anti-oxidant. While it is not 
mitochondrially targeted, there is a possibility that by quenching ROS it facilitates the 
modulation of oxysterols and mChol for therapeutic benefit. This strategy has not been 
tested in neurological conditions but warrants further investigation on this. 
The interest in LXRs as therapeutic targets has steadily increased for a multitude of 
diseases ranging from vascular to metabolic and the neurological ones. Potent and 
selective LXR ligands continue to emerge from screening of small molecule libraries, 
rational  design  and  empirical  medicinal  chemistry  approaches.  In  spite  of  this, 
 
challenges remain in minimizing undesirable effects of LXR activation on lipid 
metabolism (Komati, Spadoni, Zheng, Sridhar, Riley & Wang, 2017) for which a 
mitochondrial health assay approach may prove useful to implement drug screening 
(Figure 2). 
 
Conclusions and Perspectives 
 
All these evidences indicate that mChol has been well studied in the context of 
steroidogenesis but largely ignored in neurodegeneration. While there are the known 
functions of (i) precursor to steroids (ii) ER-MAM and (iii) Mitochondrial-Lysosomal 
interaction, as well as (iv) mtDNA tethering, there are other biochemical or 
mechanobiological processes that involve homeostasis of the cholesterol in the 
mitochondria which remain il-defined. 
With the revelation that ER-MAMs are important in AD (i), the mitochondria-lysosomal 
interaction is compromised in PD (ii), and disruption of oxysterol signalling can lead to 
ALS (iii), mChol stands as a logical target to inform and treat these conditions. 
Furthermore, a dissection of oxysterol signalling could per se lead to identification of 
potential therapeutic avenues in neurodegeneration. The genetic evidence in ALS 
advocate for this to be the case as equally strong are those from studies with SOD1 
mutants as well as LXR-–/– mice: lack of ROS neutralization as well as dysregulated 
oxysterol signalling lead to motor neuron degeneration (Abdel-Khalik et al., 2017; 
Mouzat et al., 2018; Mouzat, Raoul, Polge, Kantar, Camu & Lumbroso, 2016). Most 
notably, increasing anti-oxidant levels improve the tone of cholesterol signalling via 
LXR leading to a beneficial outcome in neurodegeneration (Bond, Bernhardt, Madria, 
Sorrentino, Scelsi & Mitchell, 2018; Sandoval-Hernandez, Restrepo, Cardona-Gomez 
& Arboleda, 2016; Stachel et al., 2016). Along with the need to continue gathering 
evidences on the beneficial effect of cholesterol modulating agents on 
neurodegeneration, it is therefore pivotal assessing novel means of measure of 
neuroprotection such as handling of the lipid by mitochondria. 
 
 
 
 
Nomenclature of Targets and Ligands 
 
 
 
Key protein targets and ligands in this article are hyperlinked to corresponding entries 
in http://www.guidetopharmacology.org,  the  common  portal  for  data  from  the 
12 
 
 
IUPHAR/BPS Guide to PHARMACOLOGY (Harding et al., 2018), and are 
permanently archived in the Concise Guide to PHARMACOLOGY 2017/18 (Alexander 
et al., 2017). 
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Figure 1. The pivotal role of cholesterol in cellular physiology and pathology 
Cholesterol (green) serves multiple purposes in the mitochondria (i) As a structural 
component of the inner and outer mitochondrial membrane (OMM, IMM) (ii) As a precursor 
of steroidogenesis, of which the first steps are conducted in the mitochondrial lumen (iii) As 
providing the platform for interorganellar interaction with endoplasmic reticulum (ER), 
Lysosomes (LY) and other intracellular compartments, and (iv) as the tether for mitochondrial 
DNA (mtDNA). 
 
 
 
Figure 2. Cholesterol interplay between mitochondria and cytosol 
The picture depicts the prominent mechanisms of cholesterol import (e.g. TSPO) in the 
mitochondria exploited by the intracellular accumulation of APOE. The two isoforms of the 
transcription factor liver X receptor (LXRα and LXRβ) activated and hence translocated in the 
nucleus by the oxidized derivatives of cholesterol (oxysterols), which are formed by the high 
redox stress produced by malfunctioning mitochondria are also highlighted in the scheme. 
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The table lists the ligands of the Translocator Protein (TSPO), their chemical structure, pharmacological 
effect, clinical or pre-clinical use. 
 
 
Class Compound Structure Properties 
 
 
 
 
 
 
 
4‐Phenylquinazoline‐2‐ 
carboxamides 
ER176
 
 
 
 
 
 
 
 
 
 
 
 
Benzodiazepines Ro‐5‐4864 
Aza‐isosteres of PK11195. In particular, PET 
radioligands with sensitivity to robustly 
image all three TSPO genotypes in human 
brain 
 
 
 
 
 
 
 
Sedative, neuroprotective, Agonist or partial 
agonist of TSPO with nanomolar binding 
affinity 
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Benzoxazines Etifoxine 
Anxiolytic effects, anti- neurodegenerative 
effects mediated by TSPO, PET ligand 
 
 
 
 
 
 
 
 
 
 
Cholest-4-en-3-one TRO40303 
Agonist, used in cardioprotection, ALS, 
Putatively interrupts the formation of 
mitochondrial transition pore 
 
 
 
 
 
 
 
 
Imidazopyridineacetamides DPA Ligand used for in vivo imaging of TSPO 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Indoleacetamides FGIN‐1‐27 
TSPO ligand characterized by steroidogenic 
and pro‐apoptotic activities 
 
 
 
 
 
 
 
 
 
 
 
 
 
Isoquinoline carboxamides PK11195 
 
 
 
 
 
 
 
 
 
 
 
 
N,N‐Dialkyl‐2‐phenylindol‐3‐ 
ylglyoxylamide (PIGA) 
PIGA 1128
 
TSPO antagonist with nanomolar affinity, 
widely used for characterizing expression and 
function in various tissues and cells, Widely 
used PET ligand 
 
 
 
 
 
 
 
 
Used to modify steroidogenic activity of 
TSPO, specifically in relation to 
neurosteroids. Developed for anxiolytic 
activity. 
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Phenoxyphenylacetamides PBR28 
Developed as PET ligands for TSPO, 
specifically used for neuroinflammation. 
Brain penetrant. 
 
 
 
 
 
 
 
Phenylpurines Emapunil Ligand with rapid anxiolytic effects 
 
 
 
 
 
 
 
 
Pyrrolobenzoxazepines OXA‐17 
Developed as anti-cancer therapies, some 
activity for cannabinoid receptors. 
 
 
 
 
 
 
Quinoline carboxamides VCM198M             Used as radioligand for TSPO imaging 
 
 
 
 
 
 
 
 
 
 
 
 
 
Vinca alkaloids Vinpocetine 
Ligand with neuroprotective activity that 
binds TSPO and other receptors such as 
adrenergic receptors 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
